Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder

Citations Over TimeTop 10% of 2013 papers

Abstract

Schizophrenia and bipolar disorder are major psychiatric disorders with high heritability and overlapping genetic variance. Here we perform a genome-wide association study in an ethnically homogeneous cohort of 904 schizophrenia cases and 1,640 controls drawn from the Ashkenazi Jewish population. We identify a novel genome-wide significant risk locus at chromosome 4q26, demonstrating the potential advantages of this founder population for gene discovery. The top single-nucleotide polymorphism (SNP; rs11098403) demonstrates consistent effects across 11 replication and extension cohorts, totalling 23, 191 samples across multiple ethnicities, regardless of diagnosis (schizophrenia or bipolar disorder), resulting in Pmeta=9.49 × 10(-12) (odds ratio (OR)=1.13, 95% confidence interval (CI): 1.08-1.17) across both disorders and Pmeta=2.67 × 10(-8) (OR=1.15, 95% CI: 1.08-1.21) for schizophrenia alone. In addition, this intergenic SNP significantly predicts postmortem cerebellar gene expression of NDST3, which encodes an enzyme critical to heparan sulphate metabolism. Heparan sulphate binding is critical to neurite outgrowth, axon formation and synaptic processes thought to be aberrant in these disorders.

Related Papers

• → Hints of hidden heritability in GWAS(2010)287 cited
• → Methods for Investigating Gene-Environment Interactions in Candidate Pathway and Genome-Wide Association Studies(2010)161 cited
• → The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes(2012)52 cited
• → Hope for GWAS: Relevant Risk Genes Uncovered from GWAS Statistical Noise(2014)2 cited
• Why odds ratio estimates of GWAS are almost always close to 1.0(2012)